Therapies used in first-line and subsequent lines of treatment and clinical responses
| All lines of treatment . | n . | Clinical responses, n (%) . | |||
|---|---|---|---|---|---|
| CR . | PR . | SD . | Progression . | ||
| IVIg | 55 | 5 (9) | 24 (44) | 16 (29) | 10 (18) |
| IVIg and rituximab | 7 | 1 (14) | 1 (14) | 4 (58) | 1 (14) |
| Rituximab-based regimens | 19 | 3 (16) | 7 (36) | 6 (32) | 3 (16) |
| Monotherapy | 13 | 1 (8) | 6 (46) | 4 (31) | 2 (15) |
| Rituximab, cyclophosphamide | 2 | 0 (0) | 1 (50) | 0 (0) | 1 (50) |
| Rituximab, fludarabine | 2 | 1 (50) | 0 (0) | 1 (50) | 0 (0) |
| Rituximab, corticoids | 1 | 1 (100) | 0 (0) | 0 (0) | 0 (0) |
| Rituximab, ibrutinib | 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
| Corticosteroids | 15 | 0 (0) | 2 (13) | 2 (13) | 11 (74) |
| Immunosuppressive therapies | 15 | 0 (0) | 0 (0) | 4 (27) | 11 (73) |
| Azathioprine | 6 | 0 (0) | 0 (0) | 2 (33) | 4 (67) |
| Cyclophosphamide | 6 | 0 (0) | 0 (0) | 2 (33) | 4 (67) |
| Cyclosporine | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Mycophenolate mofetil | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Methotrexate | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Plasma exchange | 10 | 1 (10) | 3 (30) | 0 (0) | 6 (60) |
| Chlorambucil | 9 | 0 (0) | 3 (33) | 0 (0) | 6 (67) |
| Other chemotherapy regimens | 5 | 0 (0) | 2 (67) | 1 (33) | 0 (0) |
| CHOP | 3 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Fludarabine, cyclophosphamide | 1 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Ibrutinib | 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
| Total | 135 | 10 (8) | 42 (32) | 33 (25) | 48 (35) |
| All lines of treatment . | n . | Clinical responses, n (%) . | |||
|---|---|---|---|---|---|
| CR . | PR . | SD . | Progression . | ||
| IVIg | 55 | 5 (9) | 24 (44) | 16 (29) | 10 (18) |
| IVIg and rituximab | 7 | 1 (14) | 1 (14) | 4 (58) | 1 (14) |
| Rituximab-based regimens | 19 | 3 (16) | 7 (36) | 6 (32) | 3 (16) |
| Monotherapy | 13 | 1 (8) | 6 (46) | 4 (31) | 2 (15) |
| Rituximab, cyclophosphamide | 2 | 0 (0) | 1 (50) | 0 (0) | 1 (50) |
| Rituximab, fludarabine | 2 | 1 (50) | 0 (0) | 1 (50) | 0 (0) |
| Rituximab, corticoids | 1 | 1 (100) | 0 (0) | 0 (0) | 0 (0) |
| Rituximab, ibrutinib | 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
| Corticosteroids | 15 | 0 (0) | 2 (13) | 2 (13) | 11 (74) |
| Immunosuppressive therapies | 15 | 0 (0) | 0 (0) | 4 (27) | 11 (73) |
| Azathioprine | 6 | 0 (0) | 0 (0) | 2 (33) | 4 (67) |
| Cyclophosphamide | 6 | 0 (0) | 0 (0) | 2 (33) | 4 (67) |
| Cyclosporine | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Mycophenolate mofetil | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Methotrexate | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Plasma exchange | 10 | 1 (10) | 3 (30) | 0 (0) | 6 (60) |
| Chlorambucil | 9 | 0 (0) | 3 (33) | 0 (0) | 6 (67) |
| Other chemotherapy regimens | 5 | 0 (0) | 2 (67) | 1 (33) | 0 (0) |
| CHOP | 3 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Fludarabine, cyclophosphamide | 1 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Ibrutinib | 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
| Total | 135 | 10 (8) | 42 (32) | 33 (25) | 48 (35) |